Bariatric Surgery on obesity-and Diabetes-associated Abnormalities of Hemostasis, Inflammation and Vascular Function.

Surgery Clinical Trial

— FIBRINO  

Official title:

Effects of Bariatric Surgery on obesity-and Diabetes-associated Abnormalities of Hemostasis, Inflammation and Vascular Function.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06071559
• Other study ID #: 2014/1793-31/1
• Status: Completed
• Phase: N/A
• Start date: January 1, 2015
• Est. completion date: June 1, 2022

Study information

• Verified date: October 2023
• Source: Ersta Diakoni
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this prospective cohort study is to examine circulating biomarkers before and after weight loss in patients with obesity, with or without concomitant diabetes, undergoing bariatric surgery. The main questions that are being addressed are: - Do biomarkers of hemostasis, including coagulation, fibrinolysis, and platelet function improve following surgery and if so, is that improvement more pronounced in patients with diabetes? - Do biomarkers of endothelial function and other aspects of vascular function improve following surgery and if so, is that improvement more pronounced in patients with diabetes? - Do biomarkers of inflammation, including markers of adipocyte function, improve following surgery and if so, is that improvement more pronounced in patients with diabetes? - The possible role of circulating extracellular vesicles reflecting biological functions above will also be investigated (optional) Participants will be asked to attend in total five study visits before and after surgery including a final visit at two years post-surgery. Comparisons will be performed within- as well as between groups.

Description:

In this single centre, prospective, parallel group, cohort study, patients meeting the eligibility criteria are recruited at the department of surgery at Ersta hospital, Stockholm, Sweden. Patients with obesity and type 2 diabetes (T2D) are matched for age and sex with the group of patients with obesity without T2D. During the study the participants attend five study visits: at baseline, at the morning of surgery (after two weeks of low calory diet), 6 weeks, 1 year and 2 years after surgery. At each study visit a nurse records blood pressure, weight, height, and waist/hip circumferences. In addition, the nurse recalls the medical history and any medication use including contraceptive hormones and analgesics. Fat mass is determined using bioelectric impedance. Venous blood samples are collected with the patients in the supine position after overnight fasting and at least 20 minutes of rest. For later analyses, 25 mL of blood is collected in citrate tubes and centrifuged for 20 min at 2000 x g in room temperature. Plasma aliquots are subsequently stored at minus 80 degrees Celsius. Blood test regarding values at baseline (not the primary outcome variables) will be analysed at the local hospital laboratory. Examples of those basic variables are concentrations of glucose, insulin, blood cell counts and lipids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: June 1, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

• Age 18-70 years old
• Planned for Roux-en-y gastric bypass surgery
• Obesity fulfilling criteria for bariatric surgery (according to the European Association for the Study of Obesity guidelines, ref. Yumuk et al. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-42.)

Exclusion criteria:

• Ongoing treatment with anticoagulant medication
• Ongoing treatment with antiplatelet medication other than acetylsalicylic acid
• Type 1 diabetes

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Coagulation Disorder
• Diabetes Complications
• Diabetes Mellitus
• Hemostatic Disorders
• Inflammation
• Obesity
• Obesity Associated Disorder
• Surgery

Intervention

Procedure:
• Laparoscopic Roux-en-y gastric bypass
Obesity surgery

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Ersta Diakoni	Karolinska Institutet

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood tests for endothelial function comparing two years after surgery with baseline (below referred to as "changes in").	Outcome measure: Change in Hyaluronan (ng/ml); Change in Syndacan-1 (ng/ml); Change in E-selectin (ng/ml); Change in Thrombomodulin (pg/ml); Change in von Willebrand factor (%)	before surgery - 2 years after surgery
Primary	Blood tests for fibrinolysis comparing two years after surgery with baseline (below referred to as "changes in").	Outcome measure: Change in PAI-1 activity (IU/ml); Change in Fibrinogen (pg/ml); Change in tPA activity (IU/ml); Change in PAP complex (ng/ml); Change in turbidimetric values - LagC (s); Change in turbidimetric values - LagL (s); Change in turbidimetric values - MaxAbsC (au); Change in turbidimetric values - MaxAbsL (au; Change in turbidimetric values - Lys50MA (s); Change in turbidimetric values - CRC (au/s); Change in turbidimetric values - CRL (au/s)	before surgery - 2 years after surgery
Primary	Blood tests for inflammation comparing two years after surgery with baseline (below referred to as "changes in").	Outcome measure: Change in high sensitivity CRP (microg/ml); Change in soluble IL6 receptor (ng/mL); Change in IL6 (pg/mL); Change in soluble gp130 (ng/mL); Change in TNFalfa (pg/ml)	before surgery - 2 years after surgery
Primary	Blood tests for extracellular vesicles comparing two years after surgery with baseline (below referred to as "changes in").	Exploratory analyses of extracellular vesicles (EV) in plasma using flow cytometry. EV exposing antigens of cell specific origin and/or biologically active molecules will be assessed. Outcome measure: Change in number of EVs (number of EV/micoL)	before surgery - 2 years after surgery